Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022
04 November 2022 - 7:00AM
Business Wire
- Innate will share preliminary results of the cohort
evaluating lacutamab in Sezary syndrome patients post-mogamulizumab
from the ongoing TELLOMAK Phase 2 trial
- Chief Scientific Officer, Eric Vivier, DVM, PhD, to give an
oral presentation on multispecific antibodies platform:
ANKETTM
- Partner Sanofi will display two posters on SAR’579/IPH6101
and SAR’514/IPH6401
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) today announced that the
following presentations will be presented at the 64th ASH (American
Society Hematology) Annual Meeting taking place from December
10-13, 2022, in New Orleans, Louisiana.
- Lacutamab in patients with advanced Sezary syndrome: results
from an interim analysis of the TELLOMAK phase 2 trial
- Abstract Number: 1631
- Session Name: 626. Aggressive Lymphomas: Prospective
Therapeutic Trials: Poster I
- Session Date and Time: Saturday, December 10, 2022, 5:30 PM -
7:30 PM
- Location: Ernest N. Morial Convention Center, Hall D
- Presenter: Dr Pierluigi Porcu, Director, Division of Medical
Oncology and Hematopoietic Stem Cell Transplantation, Thomas
Jefferson University Hospitals, Philadelphia
- Scientific Symposia: Antibody-Based NK Cell Engager
Therapeutics
- Session Title: Biology and Translation of NK Cells
- Session date and Time: Saturday December 10th, 2022, 2:00 PM -
3:15 PM
- Location: Ernest N. Morial Convention Center, 293-294
- Presenter: Eric Vivier, DVM, PhD, Chief Scientific Officer of
Innate Pharma
- An open-label, first-in-human, dose-escalation study of
SAR443579 administered as single agent by intravenous infusion in
patients with relapsed or refractory acute myeloid leukemia (R/R
AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk
myelodysplasia (HR-MDS) (Sanofi)
- Abstract Number: 3329
- Session Name: 704. Cellular Immunotherapies: Early Phase and
Investigational Therapies: Poster II
- Session Date and Time: Sunday, December 11, 2022, 6:00 PM -
8:00 PM
- Location: Ernest N. Morial Convention Center, Hall D
- Presenter: Anthony Stein, MD
- The Novel Trifunctional Anti-BCMA NK Cell Engager SAR’514
Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK
Cell Engagement (Sanofi)
- Abstract Number: 4486
- Session Name: 651. Multiple Myeloma and Plasma Cell Dyscrasias:
Basic and Translational: Poster III
- Session Date and Time: Monday, December 12, 2022, 6:00 PM -
8:00 PM
- Location: Ernest N. Morial Convention Center, Hall D
- Presenter: Alexandre Tang, Ph.D
The posters and presentation will be available on the
Publications section of innate-pharma.com following the
meeting.
About Lacutamab:
Lacutamab is a first-in-class anti-KIR3DL2 humanized
cytotoxicity-inducing antibody that is currently in clinical trials
for treatment of cutaneous T-cell lymphoma (CTCL), an orphan
disease, and peripheral T cell lymphoma (PTCL). Rare cutaneous
lymphomas of T lymphocytes has a poor prognosis with few
efficacious and safe therapeutic options at advanced stages.
KIR3DL2 is an inhibitory receptor of the KIR family, expressed
by approximately 65% of patients across all CTCL subtypes and
expressed by up 90% of patients with certain aggressive CTCL
subtypes, in particular, Sézary syndrome. It is expressed by up to
50% of patients with mycosis fungoides and peripheral T-cell
lymphoma (PTCL). It has a restricted expression on normal
tissues.
Lacutamab is granted European Medicines Agency (EMA) PRIME
designation and US Food and Drug Administration (FDA) granted Fast
Track designation for the treatment of patients with relapsed or
refractory Sézary syndrome who have received at least two prior
systemic therapies.
About ANKETTM:
ANKETTM (Antibody-based NK cell Engager
Therapeutics) is Innate's proprietary platform for
developing next-generation, multi-specific natural killer (NK) cell
engagers to treat certain types of cancer.
This versatile, fit-for-purpose technology is creating an
entirely new class of molecules to induce synthetic immunity
against cancer. It leverages the advantages of harnessing NK cell
effector functions against cancer cells and also provides
proliferation and activation signals targeted to NK cells.
Our latest innovation, the tetra-specific ANKET molecule, is the
first NK cell engager technology to engage activating receptors
(NKp46 and CD16), a tumor antigen and an interleukin-2 receptor
(via an IL-2 variant, IL-2v) via a single molecule.
About Innate Pharma:
Innate Pharma S.A. is a global, clinical-stage oncology-focused
biotech company dedicated to improving treatment and clinical
outcomes for patients through therapeutic antibodies that harness
the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies includes several
potentially first-in-class clinical and preclinical candidates in
cancers with high unmet medical need.
Innate is a pioneer in the understanding of Natural Killer cell
biology and has expanded its expertise in the tumor
microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com
Information about Innate Pharma shares:
ISIN code Ticker
code LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors:
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts and the Company’s continued
ability to raise capital to fund its development. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2021,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221103006229/en/
Investors and Media
Innate Pharma Henry Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr NewCap Arthur Rouillé Tel.:
+33 (0)1 44 71 00 15 innate@newcap.eu
Innate Pharma (EU:IPH)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Innate Pharma (EU:IPH)
Historical Stock Chart
Von Apr 2023 bis Apr 2024